Navigation Links
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
Date:5/28/2008

SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) will present data from ongoing clinical trials of voreloxin (formerly SNS-595) at two major upcoming oncology conferences.

Updated interim data from Sunesis' ongoing Phase 2 clinical trial of voreloxin in platinum-resistant ovarian cancer patients will be presented during the 44th American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2008 in Chicago, Illinois.

Updated results and a comparative safety and response analysis in older patients (>/= 60 years old) and younger patients (< 60 years old) from the company's Phase 1 clinical trial of voreloxin in relapsed or refractory acute leukemia patients will be presented at the 13th Congress of the European Hematology Association (EHA) being held June 12 - 15, 2008 in Copenhagen, Denmark. The presentation will also include preliminary data from the company's Phase 1b trial of voreloxin combined with cytarabine in relapsed/refractory acute myeloid leukemia (AML) patients. In addition, data from the company's ongoing Phase 1 clinical trial of SNS-032 in patients with chronic lymphocytic leukemia and multiple myeloma will be presented at EHA.

44th ASCO Annual Meeting

o A PHASE 2 TRIAL OF SNS-595 IN WOMEN WITH PLATINUM RESISTANT EPITHELIAL

OVARIAN CANCER

Abstract #5582

General poster session Gynecologic Cancer: Ovarian Cancer

Saturday, May 31, 2008, 8:00 a.m. - 12:00 p.m. CST, S Hall A1

13th Congress of the European Hematology Association

o SAFETY AND EFFICACY EXPERIENCE OF SNS-595 IN RELAPSED/REFRACTORY ACUTE

LEUKEMIA PATIENTS >/= 60 YEARS OLD COMPARED TO < 60 YEARS OLD: RESULTS

OF A PHASE 1 STUDY

Abstract #0515

Poster session 2: Acute myeloid leukemia -- Clinical II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

o A PHASE 1 TRIAL OF SNS-032, A POTENT AND SPECIFIC CDK 2, 7 AND 9

INHIBITOR, IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

Abstract #0792

Poster session 2: Novel therapies, drug resistance and pharmacology II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

All clinical data presented will be available following each conference on the Sunesis corporate website at http://www.sunesis.com.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling.

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

SNS-032, Sunesis' potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in chronic lymphocytic leukemia and multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 22, 2017 Research and Markets has ... Market (Thermometers - Digital, Infrared, Mercury; Trend Indicator):Analysis By Region, By ... ... is forecasted to grow at a CAGR of 5.33% during 2016-2021 ... of infectious diseases along with surging demand of digital thermometer. Apart ...
(Date:2/22/2017)... Oncternal Therapeutics, Inc., a clinical-stage biotechnology ... common malignancies, today announced the closing of an ... to use the proceeds to further clinical development ... preclinical development of a new ROR1-targeted antibody-drug conjugate ... anti-ROR1 monoclonal antibody being developed to treat patients ...
(Date:2/22/2017)... , Feb. 22, 2017 Kineta, ... development of novel immune modulating therapies, today announced ... a9a10 nicotinic acetylcholine receptor (nAChR), demonstrates robust chronic ... pain models. The study also establishes the a9a10 ... treatment of chronic pain. The findings were reported ...
Breaking Medicine Technology:
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... ... American adults with chronic conditions reported skipping doses or not filling a prescription ... uninsured or under-insured, rates of cost-related problems getting medications were 30-60%*. ...
(Date:2/22/2017)... PA (PRWEB) , ... February 22, 2017 , ... Sideline ... where the company met national TV host Tom Seay and his production crew. ... a favorite among equestrians around the world. Saddle Sidekicks will be featured on ...
(Date:2/22/2017)... ... February 22, 2017 , ... The first-ever National Heart ... advocates, and individuals join together to increase recognition about the risks of heart ... , “Today we mark a nationwide movement to raise awareness about a disease ...
(Date:2/22/2017)... MADISON HEIGHTS, MICHIGAN (PRWEB) , ... February 22, ... ... news and analysis of issues related to spine practices, is featuring Michigan neurosurgeon ... Jagannathan is known as one of a small number of neurosurgeons in Michigan ...
(Date:2/22/2017)... ... 22, 2017 , ... Michael J. Hennessy Associates, Inc. (MJH ... technology professionals and other key stakeholders with an array of valuable resources, Healthcare ... 1, announced Michael J. Hennessy, Jr., president of MJH Associates. , In ...
Breaking Medicine News(10 mins):